Xencor to Host Second Quarter 2021 Financial Results Webcast and Conference Call on August 4, 2021

Xencor management will host a webcast and conference call the same day at 4:30 p.m.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Wednesday, July 28, 2021
Information
Tags: 
Biotechnology, Health, Genetics, Pharmaceutical, Oncology, Life sciences, Medical specialties, Clinical medicine, Immunology, Biotechnology, Immune system, Monoclonal antibody, Biopharmaceutical, Autoimmunity
Geotags: 
United States, California
⚠ generated by AI ↴
Organisation: 
XENCOR, INC.
Summary
Key Points: 
  • Xencor management will host a webcast and conference call the same day at 4:30 p.m.
  • ET (1:30 p.m. PT) to discuss the financial results and provide a corporate update.
  • A live webcast of the conference call will be available under "Events & Presentations" in the Investors section of the Company's website located at www.xencor.com .
  • Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases.


Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that it will release second quarter 2021 financial results after the market closes on Wednesday, August 4, 2021.

Xencor management will host a webcast and conference call the same day at 4:30 p.m. ET (1:30 p.m. PT) to discuss the financial results and provide a corporate update.

The live call may be accessed by dialing (877) 359-9508 for domestic callers or (224) 357-2393 for international callers and referencing conference ID number 1389708. A live webcast of the conference call will be available under "Events & Presentations" in the Investors section of the Company's website located at www.xencor.com. The webcast will be archived on the company website for 30 days.

About Xencor, Inc.

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases. Currently, 22 candidates engineered with Xencor's XmAb® technology are in clinical development internally and with partners. Xencor's XmAb antibody engineering technology enables small changes to the structure of proteins resulting in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.

Copyright: 
Copyright Business Wire 2021